Clinical Trials Logo

Migraine, Acute clinical trials

View clinical trials related to Migraine, Acute.

Filter by:
  • None
  • Page 1

NCT ID: NCT01001234 Completed - Migraine, Acute Clinical Trials

A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)

Start date: November 30, 2009
Phase: Phase 3
Study type: Interventional

This Clinical Trial evaluates the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents.

NCT ID: NCT00792636 Completed - Migraine Disorders Clinical Trials

A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period

Start date: November 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to test the effect on blood pressure of sumatriptan and naproxen sodium combination tablets, tablets containing only sumatriptan, and tablets containing only naproxen sodium when these drugs are taken to treat migraine headaches that occur during a 6-month period.

NCT ID: NCT00573170 Completed - Migraine Disorders Clinical Trials

TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults

Start date: February 2008
Phase: Phase 3
Study type: Interventional

Study TRX109011/TRX109013, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus Butalbital-containing Combination Medications (BCM) for the Acute Treatment of Migraine when administered during the Moderate-Severe Pain Phase of the Migraine (Studies 1 and 2 of 2)

NCT ID: NCT00383162 Completed - Migraine Disorders Clinical Trials

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

Start date: November 2006
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s) within the past year due to non-response or intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each attack; one attack will be treated with one tablet of the Combination Product (sumatriptan succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover design). [Study 1 of 2]

NCT ID: NCT00269022 Completed - Migraine, Acute Clinical Trials

Use Of SB-705498 In The Acute Treatment Of Migraine

Start date: January 2006
Phase: Phase 2
Study type: Interventional

Despite the success of the triptan class of drugs, approximately 60% of patients who take medication at the moderate to severe pain stage of acute migraine, still have pain of mild or greater degree at 2 hrs post dose. SB-705498 is a novel, first in class TRPV1 receptor antagonist under development for the treatment of migraine pain. Preclinical experiments have demonstrated that the TRPV1 receptor is expressed both centrally and peripherally in the trigeminal system and inhibition of TRPV1 with SB-705498 can both prevent and reverse established central sensitisation.